HHealth Read More Off-label GLP-1 use highlights the cultural pressures driving body anxietiesNovember 14, 2025 A new sociomedical perspective shows how off-label use of GLP-1 drugs for slimness is redefining what counts as…
HHealth Read More GLP-1 drugs linked to improved survival in colon cancer patientsNovember 11, 2025 A new University of California San Diego study offers compelling evidence that glucagon-like peptide-1 (GLP-1) receptor agonists –…
HHealth Read More Diabetes remission possible with GLP-1 drugs, Italian study confirmsOctober 30, 2025 Real-world data from over 14,000 Italian adults reveal that GLP-1 receptor agonists can induce remission in type 2…
HHealth Read More Exercise can mitigate depression-like behaviors induced by high-fat, high-sugar dietsOctober 21, 2025 Researchers led by Professor Yvonne Nolan at University College Cork have identified specific metabolic pathways through which exercise…
GGenetics Read More SMOC1 gene plays a surprising role in the development of type 2 diabetesOctober 8, 2025 Scientists at City of Hope®, one of the largest and most advanced cancer research and treatment organizations in…
HHealth Read More Study shows prediabetes remission does not always require weight lossOctober 1, 2025 New evidence shows that restoring normal glucose regulation can shield against diabetes even without weight loss, reshaping prevention…
HHealth Read More Study:Half of adults without diabetes taking weight-loss drug discontinue treatment within a yearSeptember 15, 2025 The new class of anti-obesity drugs, glucagon-like peptide-1 receptor agonists (GLP-1RAs), is proving remarkably effective at helping individuals…
GGenetics Read More Genetic study shows dual GIPR/GLP1R action curbs binge alcohol useSeptember 15, 2025 New genetic evidence suggests that targeting GIPR and GLP1R could reduce harmful drinking patterns while improving liver and…